Public Policy Blog

  • Ensuring Access to Treatment – Drug Pricing

    You likely have heard about the President’s Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs in the news.  The President requested comments on a broad range of potential changes to increase competition and reduce drug prices.  One thing is clear, how drug prices are created is not simple or very transparent and will depend on many factors, including your prescription benefit manager (PBM).  This complex system has been built over time and many parts of the system are interwoven and impact each other directly or indirectly.  As such, it is extremely important that any actions taken to improve the system are fully understood and that all impacts, direct and indirect, are fully assessed before enacting change.  TAA submitted comments to the Administration requesting that patient needs should be a top priority and have requested that any further action follows the official rule-making process which would allow further comments during the process.  TAA will continue to work with the National Health Council and other like-minded patient groups to ensure our voices are heard as the process moves forward.   TAA Comments HHS Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs   Meeting your Representative and

  • August Facebook Live

  • NIH Funding

  • TAA Submits Written Testimony for Labor Health and Human Services

  • Fiscal Year 2018 TS Funding Is Approved

  • 2018 Tourette Syndrome National Advocacy Day

  • Advances in Tourette Syndrome Research and Treatment

  • Tourette Syndrome Funding in Fiscal Year 18

  • The TAA appears on 90 Day Fiance!

  • Menendez Bill Ramps-Up Efforts to Develop New Treatments, Cure for Tourette Syndrome

    WASHINGTON, D.C. – U.S. Senator Bob Menendez (D-N.J.) reintroduced legislation that refocuses the National Institute of Health’s (NIH) efforts to discover new treatments and a cure for Tourette Syndrome (TS).  May 15 – June 15 is Tourette Syndrome Awareness Month. “With tens of thousands of our children and teens afflicted with Tourette Syndrome, this debilitating disorder deserves greater attention from our nation’s scientific research institutions,” said Sen. Menendez.  “We must do everything we can to develop effective treatments and a cure for TS to help ease the suffering and help unlock every child’s full potential.” The Tourette Association currently estimates that one out of every 160 American children between the ages of five and 17 has TS.  When including other tic disorders, the prevalence is estimated to be about one percent of all U.S. children. Sen. Menendez’s CARE for Tourette Syndrome Act seeks to build on current NIH activities on TS and directs NIH to allocate existing funds towards critical research programs by: Expanding and intensifying data collection on TS to improve information on the prevalence of the disease, including data on comorbid conditions and variations in the disease across populations and geographic regions Establishing Collaborative Research Centers for Tourette